NO20021410L - Forebygging og behandling av blodkoagulasjons-relaterte sykdommer - Google Patents

Forebygging og behandling av blodkoagulasjons-relaterte sykdommer

Info

Publication number
NO20021410L
NO20021410L NO20021410A NO20021410A NO20021410L NO 20021410 L NO20021410 L NO 20021410L NO 20021410 A NO20021410 A NO 20021410A NO 20021410 A NO20021410 A NO 20021410A NO 20021410 L NO20021410 L NO 20021410L
Authority
NO
Norway
Prior art keywords
hypercoagulant
persistent
animal
diseases
state
Prior art date
Application number
NO20021410A
Other languages
English (en)
Other versions
NO20021410D0 (no
Inventor
Hiroyuki Saito
Takehisa Kitazawa
Kazutaka Yoshihashi
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20021410D0 publication Critical patent/NO20021410D0/no
Publication of NO20021410L publication Critical patent/NO20021410L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Ecology (AREA)

Abstract

Det er fremskaffet et dyr med en vedvarende hyperkoagulerende tilstand ved å overføre en celle, for eksempel en tumorcelle, som genet til human vevsfaktor er inkorporert i til et forsøksdyr, slik som en mus, og deretter la nevnte celle vokse og tilføre human vevsfaktor kontinuerlig til nevnte forsøksdyr. Denne dyremodellen er egnet for forskning og utvikling av terapeutiske agenser for sykdommer som har en vedvarende hyperkoagulerende tilstand. Den foreliggende oppfinnelsen tilveiebringer også forebyggende eller terapeutiske agenser for sykdommer som har en vedvarende hyperkoagulerende tilstand, en hyperkoagulerende tilstand som skyldes infeksjoner, venøs trombose, arteriell trombose og sykdommer som er et resultat av hypertrofien av vaskulære vev, der nevnte agens innbefatter et antistoff mot human vevsfaktor (human TF) som en aktiv bestanddel.
NO20021410A 1999-10-01 2002-03-21 Forebygging og behandling av blodkoagulasjons-relaterte sykdommer NO20021410L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP28184399 1999-10-01
JP28213499 1999-10-01
JP28216799 1999-10-01
JP28212099 1999-10-01
JP28219299 1999-10-01
JP28218899 1999-10-01
PCT/JP2000/006802 WO2001024626A1 (fr) 1999-10-01 2000-09-29 Prevention et traitement de maladies associees a la coagulation sanguine

Publications (2)

Publication Number Publication Date
NO20021410D0 NO20021410D0 (no) 2002-03-21
NO20021410L true NO20021410L (no) 2002-05-24

Family

ID=27554423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021410A NO20021410L (no) 1999-10-01 2002-03-21 Forebygging og behandling av blodkoagulasjons-relaterte sykdommer

Country Status (18)

Country Link
US (2) US8062638B1 (no)
EP (2) EP1222854B1 (no)
JP (1) JP3859512B2 (no)
KR (1) KR20030008205A (no)
AT (1) ATE498305T1 (no)
AU (1) AU7450600A (no)
BR (1) BR0014667A (no)
CA (1) CA2388408A1 (no)
CZ (1) CZ20021035A3 (no)
DE (1) DE60045638D1 (no)
DK (1) DK1222854T3 (no)
HU (1) HUP0203486A2 (no)
IL (1) IL148980A0 (no)
MX (1) MXPA02003278A (no)
NO (1) NO20021410L (no)
PL (1) PL354961A1 (no)
SK (1) SK4442002A3 (no)
WO (1) WO2001024626A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20040180051A1 (en) * 2001-03-26 2004-09-16 Koji Suzuki Blood rheology improving agents
JP4683821B2 (ja) 2001-05-18 2011-05-18 中外製薬株式会社 ヒト組織因子を産生するノックイン非ヒト動物
PL368989A1 (en) * 2001-10-02 2005-04-04 Novo Nordisk A/S Human tissue factor antibodies
US20060233786A1 (en) * 2002-05-23 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3865418B2 (ja) 1994-07-13 2007-01-10 中外製薬株式会社 ヒトインターロイキン−８に対する再構成ヒト抗体
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU744146B2 (en) 1996-09-26 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
BR9909382A (pt) * 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
KR20030008205A (ko) 2003-01-24
JP3859512B2 (ja) 2006-12-20
PL354961A1 (en) 2004-03-22
EP1222854B1 (en) 2011-02-16
IL148980A0 (en) 2002-11-10
AU7450600A (en) 2001-05-10
SK4442002A3 (en) 2003-04-01
CA2388408A1 (en) 2001-04-12
DK1222854T3 (da) 2011-03-14
US8062638B1 (en) 2011-11-22
BR0014667A (pt) 2002-07-02
NO20021410D0 (no) 2002-03-21
WO2001024626A1 (fr) 2001-04-12
EP1222854A1 (en) 2002-07-17
ATE498305T1 (de) 2011-03-15
EP1222854A4 (en) 2006-07-05
CZ20021035A3 (cs) 2002-08-14
DE60045638D1 (de) 2011-03-31
HUP0203486A2 (hu) 2003-02-28
MXPA02003278A (es) 2002-09-02
US20120073002A1 (en) 2012-03-22
EP2351483A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
Baron et al. Optimal support of wound healing: New Insights
Jackson et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing
Schuppan et al. Hepatic fibrosis: from bench to bedside
US10864229B2 (en) Use of nitrite salts in chronic ischemia
MEP10508A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Akasaka et al. Homocysteine promotes p38-dependent chemotaxis in bovine aortic smooth muscle cells
NO20021410L (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
Ennis et al. A biochemical approach to wound healing through the use of modalities
US20140242194A1 (en) Use of nitrite salts in treating tissue damage
Kalay et al. Effect of bone morphogenic protein-2 and desferoxamine on distraction osteogenesis
DE60325261D1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
Englesbe et al. Interleukin-1β inhibits PDGF-BB− induced migration by cooperating with PDGF-BB to induce cyclooxygenase-2 expression in baboon aortic smooth muscle cells
KR101816964B1 (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
Colston et al. Impact of brief oxidant stress on primary adult cardiac fibroblasts
Guzmán‐Valdivia Gómez et al. Prevention of postoperative abdominal adhesions using systemic enoxaparin and local diclofenac. An experimental study
WO2006020912A3 (en) Treatments for congestive heart failure
Marx Angiogenesis research comes of age: The discovery of agents that stimulate angiogenesis—the growth of new blood vessels—has sparked interest in the research
Silver et al. Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo
Weinreich et al. Effects of isoniazid and niacin on experimental wound-healing
Tondi et al. Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1)
Perrée et al. Function and structure of pressurized and perfused porcine carotid arteries: effects of in vitro balloon angioplasty
Ondrick et al. Angiogenesis
Jain et al. Autophagy inhibition by chloroquine prevents increase in blood pressure and preserves endothelial functions
Góralczyk et al. Effect of low level laser irradiation on VEGF gene expression in cultured endothelial cells
Donati et al. Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application